Drug Profile


Alternative Names: ABL 001

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis Oncology
  • Class Antineoplastics; Pyrazoles; Pyrrolidines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia; Chronic myeloid leukaemia

Most Recent Events

  • 21 Apr 2017 Chemical structure information added
  • 13 Apr 2017 Novartis Pharmaceuticals plans a phase III trial for Chronic myeloid leukaemia (Second-line therapy or greater) (PO) (NCT03106779)
  • 04 Apr 2017 Novartis intends to submit NDA to the US FDA for Chronic myeloid leukaemia in 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top